406 related articles for article (PubMed ID: 26661938)
1. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
3. What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?
Muhammad A; van der Lely AJ; O'Connor RD; Delhanty PJ; Dal J; Dallenga AH; Feelders RA; Janssen JA; Jorgensen JO; Neggers SJ
Eur J Endocrinol; 2016 May; 174(5):663-7. PubMed ID: 26903550
[TBL] [Abstract][Full Text] [Related]
4. A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.
Franck SE; Korevaar TIM; Petrossians P; Daly AF; Chanson P; Jaffrain-Réa ML; Brue T; Stalla GK; Carvalho D; Colao A; Hána V; Delemer B; Fajardo C; van der Lely AJ; Beckers A; Neggers SJCMM
Eur J Endocrinol; 2017 Apr; 176(4):421-431. PubMed ID: 28100630
[TBL] [Abstract][Full Text] [Related]
5. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
Neggers SJ; Franck SE; de Rooij FW; Dallenga AH; Poublon RM; Feelders RA; Janssen JA; Buchfelder M; Hofland LJ; Jørgensen JO; van der Lely AJ
J Clin Endocrinol Metab; 2014 Oct; 99(10):3644-52. PubMed ID: 24937542
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.
Bianchi A; Valentini F; Iuorio R; Poggi M; Baldelli R; Passeri M; Giampietro A; Tartaglione L; Chiloiro S; Appetecchia M; Gargiulo P; Fabbri A; Toscano V; Pontecorvi A; De Marinis L
J Exp Clin Cancer Res; 2013 Jun; 32(1):40. PubMed ID: 23799893
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
Neggers SJ; van der Lely AJ
Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
[TBL] [Abstract][Full Text] [Related]
10. Pegvisomant in acromegaly: a multicenter real-life study in Argentina.
Basavilbaso NXG; Ballarino MC; Bruera D; Bruno OD; Chervin AB; Danilowicz K; Fainstein-Day P; Fidalgo SG; Frigeri A; Glerean M; Guelman R; Isaac G; Katz DA; Knoblovits P; Librandi F; Montes ML; Mallea-Gil MS; Manavela M; Mereshian P; Moncet D; Pignatta A; Rogozinsky A; Sago LR; Servidio M; Spezzi M; Stalldecker G; Tkatch J; Vitale NM; Guitelman M
Arch Endocrinol Metab; 2019 Aug; 63(4):320-327. PubMed ID: 31460622
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
[TBL] [Abstract][Full Text] [Related]
12. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
14. Hypothesis: Extra-hepatic acromegaly: a new paradigm?
Neggers SJ; Kopchick JJ; Jørgensen JO; van der Lely AJ
Eur J Endocrinol; 2011 Jan; 164(1):11-6. PubMed ID: 21045065
[TBL] [Abstract][Full Text] [Related]
15. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
Franck SE; Broer L; van der Lely AJ; Kamenicky P; Bernabéu I; Malchiodi E; Delhanty PJD; Rivadeneira F; Neggers SJCMM
Neuroendocrinology; 2017; 105(2):131-140. PubMed ID: 27513761
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
[TBL] [Abstract][Full Text] [Related]
17. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
Neggers SJ; de Herder WW; Feelders RA; van der Lely AJ
Pituitary; 2011 Sep; 14(3):253-8. PubMed ID: 21221818
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analog and pegvisomant combination therapy for acromegaly.
Neggers SJ; van der Lely AJ
Nat Rev Endocrinol; 2009 Oct; 5(10):546-52. PubMed ID: 19763127
[TBL] [Abstract][Full Text] [Related]
19. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
20. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
